Onkure therapeutics, inc. OKUR.US Overview
BetaUS StockHealthcare
(No presentation for OKUR)
OKUR AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
OKUR Current Performance
-4.76%
Onkure therapeutics, inc.
-1.19%
Avg of Sector
0.52%
S&P500
OKUR Key Information
OKUR Financial Forecast
Unit : USD
OKUR Earnings Table
No related data records
OKUR Profile
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.